Kabasura Kudineer Research Articles

Complementary Medication for COVID-19 Outbreak Concerns in the Leprosy Community - A Passionate Proposal

Abstract: The number of COVID-19-positive cases continues to climb, causing alarm around the world. The Nilavembu (Andrographis paniculata) Kudineer of Siddha medicine, an alternative medicine practiced in India, has already been shown to be beneficial in viral outbreaks like Chikungunya and Dengue fever. Several investigations have demonstrated that these herbs have anti-inflammatory, analgesic, antipyretic, antibacterial, and antiviral activities against the Herpes simplex virus and Ebstein Barr virus. This herbal remedy has also been shown to have a low risk of negative side effects. There is currently no approved pharmaceutical treatment for COVID-19. Using the phrases 'COVID-19,' 'Ayush,' 'Siddha,' and 'Leprosy,' we searched other databases such as Google, Embase, ScienceDirect, and the Clinical Trial Registry of India. In another research on Siddha treatment, Kabasura Kudineer, a decoction of 15 herbal items was discovered to have activity against the spike protein of SARS COV-2 using an in-silico compound method. As there are no effective treatments available for the prevention and treatment of mild to moderate cases, these two medicines, Nilavembu Kudineer, and Kabasura Kudineer can be used as part of a COVID-19 prophylaxis using a combination of modern and alternative medicine.

A Systematic Analysis of COVID-19 Clinical Trials Registered in the Clinical Trials Registry of India.

The Clinical Trials Registry - India (CTRI) database is a registry of various trials conducted in India and this study scrutinized the studies registered for COVID-19 from the database to detect patterns in trial design, appraising the target regions of therapiesand comprehending the terrain of research endeavors. This was a cross-sectional study that analyzed the registered trials for COVID-19 between March 2020 and September 2023. A trial search was conducted on the CTRI database to include all types of studies registered for COVID-19 with keywords like "COVID" and "coronavirus" and studies conducted on conditions other than COVID-19 were excluded. The data regarding study characteristics were noted under various sections in a preformed proforma. A total of 807 trials were taken for final analysis and there were about 344 prospective and 260 retrospective interventional trials, 35 prospective and 165 retrospective observational studies, and two prospective and one retrospective post-marketing surveillance study. The majority of the studies had duration under 12 months (91%). The maximum number of studies were registered from AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy) and allied therapies (n = 283), with about 104 types of interventions, followed by the drug category having 119 trials registered and about 57 types of interventions. Kabasura Kudineer and yoga in the AYUSH category, molnupiravir, colchicine, and favipiravir in the drug category, and tocilizumaband convalescent plasma among biologics were some common interventions used. The majority of trials did not mention the trial phase and declared it as not applicable (54%), whereas 15% were registered as phase 2 and 13% as phase 3. About 54% of the studies were randomized and randomized parallel-group design (20%) was the most common study design. Only 6% of the trials were post-graduate thesis and the majority of the trials (n = 535) denied sharing their individual participant data. Only 0.86% and 0.61% of the trials were terminated and suspended, respectively, denoting proper design and conduct of the trials. In the CTRI database, the majority of trials were prospective interventional studies, with a predominance of AYUSH therapies and drug interventions. Common interventions included Kabasura Kudineer and yoga in AYUSH, and molnupiravir, colchicine, and favipiravir in drugs. Most studies had durations under 12 months and randomized parallel-group design was the most common study design. The intention to use and promote an indigenous system of medicine looks promising in the absence of any definite therapy. A minute number of registered suspended and terminated trials might bea positive picture of meticulously designed and executed trials even during a pandemic situation in India.

The GC-MS Analysis of Kabasura Kudineer: A Vital Siddha Drug in COVID-19 Therapy

ABSTRACT Introduction: This study focuses on the gas chromatography-mass spectrometry (GC-MS) analysis of Kabasura Kudineer, a Siddha formulation renowned for its properties against cold and exclusively utilized during the coronavirus disease 2019 (COVID-19) pandemic. Methods: The medication was obtained from a reputable Siddha vendor in Chennai, India, and subsequently extracted and subjected to GC-MS analysis. Results: The GC-MS profiling revealed the presence of several molecules, including benzoic acid, eugenol, alpha-ylangeneol, trans-2,4-dimethylthiane, S, S-dioxide, humulene, methyl 4,7,10,13-hexadecatetraenoate, 17-octadecynoic acid, 1-hexadecyn-3-ol, 3,7,11,15-tetramethyl, sulfurous acid, butyl heptadecyl ester, chloroacetic acid, tetradecyl ester, n-propyl cinnamate, oleyl alcohol, trifluoroacetate, 1-heptatriacotanol, and fenretinide. These compounds exhibit expansive medicinal roles. Conclusion: Kabasura Kudineer emerges as a highly effective remedy for cold-related ailments, particularly owing to the presence of bioactive compounds such as eugenol and humulene. These constituents play pivotal roles in antimicrobial and anti-inflammatory activities. Further investigations into the individual medicinal efficacy of each identified molecule are warranted to substantiate the therapeutic potential of Kabasura Kudineer, providing valuable insights for future applications.

Qualitative and quantitative analysis of siddha herbal Formulation Kabasura kudineer in various concentrations

Introduction: Siddha system is one of the ancient systems coming practised in southern part of India, North and Eastern parts of Sri Lanka. The Siddha medicines are categorised as Aga marundhugal (Internal Medicine) and Pura marundhugal (External Medicine).One among them is kudineer (Decoction). Kabasura kudineer chooranam (KSK) is a polyherbal formulation and it contains 15 ingredients. It is indicated for Iyyasuram and it used for fever with Respiratory disease. Objective and Methods: To analyse the presents of different phyto constituents, develop HPTLC fingerfrint and quantify the amount of phenols and alkaloids in Kabasura Kudineer prepared at 1/4 (sample A), 1/8 (Sample B) and 1/16 (Sample C) reduction concentrations. Result: Phytochemical analysis of Kabasura Kudineer revealed the presence of alkaloid, phenol, flavonoid and tannin in Sample A, B and C. The Rf value obtained by TLC and HPTLC fingerprint for Sample A are 0.02, 0.04, 0.79, Sample B is 0.04, 0.80 and Sample C is 0.04, 0.43, 0.051 and 0.71. The amount of Alkaloid present in Sample A, B, C 1.61 ,1.03,1.44 and phenol present in Sample A, B, C 17.62 ,19.71,18.60 Conclusion: The Analytical parameters along with TLC photo documentation, HPTLC fingerprinting profile and UV Spectrophometer in various concentration of Kabasura Kudineeer are different in different reduction concentration ratio. Further specific chemical markers can be quantified using HPTLC and the therapeutic efficacy can be explored in further studies.

In silico anti-viral assessment of phytoconstituents in a traditional (Siddha Medicine) polyherbal formulation – Targeting Mpro and pan-coronavirus post-fusion Spike protein

Background and aimNovel nature of the viral pathogen SARS-CoV-2 and the absence of standard drugs for treatment, have been a major challenge to combat this deadly infection. Natural products offer safe and effective remedy, for which traditional ethnic medicine can provide leads. An indigenous poly-herbal formulation, Kabasura Kudineer from Siddha system of medicine was evaluated here using a combination of computational approaches, to identify potential inhibitors against two anti-SARS-CoV-2 targets – post-fusion Spike protein (structural protein) and main protease (Mpro, non-structural protein). Experimental procedureWe docked 32 phytochemicals from the poly-herbal formulation against viral post-fusion Spike glycoprotein and Mpro followed by molecular dynamics using Schrodinger software. Drug-likeness analysis was performed using machine learning (ML) approach and pkCSM. ResultsThe binding affinity of the phytochemicals in Kabasura Kudineer revealed the following top-five bioactives: Quercetin > Luteolin > Chrysoeriol > 5-Hydroxy-7,8-Dimethoxyflavone > Scutellarein against Mpro target, and Gallic acid > Piperlonguminine > Chrysoeriol > Elemol > Piperine against post-fusion Spike protein target. Quercetin and Gallic acid exhibited binding stability in complexation with their respective viral-targets and favourable free energy change as revealed by the molecular dynamics simulations and MM-PBSA analysis. In silico predicted pharmacokinetic profiling of these ligands revealed appropriate drug-likeness properties. ConclusionThese outcomes provide: (a) potential mechanism for the anti-viral efficacy of the indigenous Siddha formulation, targeting Mpro and post-fusion Spike protein (b) top bioactive lead-molecules that may be developed as natural product-based anti-viral pharmacotherapy and their pleiotropic protective effects may be leveraged to manage co-morbidities associated with COVID-19.

Effectiveness of Kabasura Kudineer tablets in the management of asymptomatic and mild cases of COVID-19: A pilot double-blinded, randomized controlled trial

IntroductionCOVID-19 was declared a pandemic in 2020. It has had a devastating effect on human life and the global economy. To date, there is no proven therapy for COVID-19, even though rigorous research is ongoing to test multiple compounds across all systems of medicine. A need was felt to systematically explore the Indian system of medicine to assess its efficacy against COVID-19. The objective of the present study was to examine the effect of Kabasura Kudineer as a standalone therapy on the following: time required to achieve symptom relief & resolution, virological clearance, and levels of IL6, CRP and IgG, and compare it to the standard therapy available for treatment of COVID-19. MethodologyA double-blinded randomized controlled trial was conducted in 110 participants. 55 participants were enrolled in the Kabasura Kudineer arm and 55 in the control (standard therapy + Kabasura Kudineer placebo) arm. Study participants were randomly allocated into the two study arms. They were assessed for symptoms at baseline, and on Day 5 and Day 10. RT PCR, CRP, IL6 and IgG levels were measured at baseline, Day 5 and Day 10. On day 28, participants were interviewed telephonically for symptom assessment alone. Statistical analysisA per-protocol approach was used. Significant difference between two groups was assessed at baseline, day 5 and day 10 using the Chi-square and Mann Whitney test. ResultA total of 110 patients participated in study. Four patients in the Kabasura Kudineer arm and 9 in the Standard therapy arm were lost to follow-up. Baseline characteristics for both the groups were matched at baseline. 83.9% and 93.9% patients were relieved of all symptoms by the 10th day in Kabasura and standard therapy groups respectively. Decrease in CRP level was more pronounced in the Kabasura group compared to standard therapy viz. 3 mg/l and 1.26 mg/l. No significant difference was found in IgG level and IL6 levels in both the study groups. However, it was noticed that among the unvaccinated group, the surge in IgG levels was much higher in Kabasura Kudineer group than the standard therapy group. ConclusionKabasura Kudineer as a standalone therapy was as effective and safe as the standard therapy among patients with asymptomatic to mild COVID-19.

Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology.

COVID-19 caused by the SARS-CoV-2 virus is widespread in all regions, and it disturbs host immune system functioning leading to extreme inflammatory reaction and hyperactivation of the immune response. Kabasura Kudineer (KSK) is preventive medicine against viral infections and a potent immune booster for inflammation-related diseases. We hypothesize that KSK and KSK similar plant compounds, might prevent or control the COVID-19 infection in the human body. 1,207 KSK and KSK similar compounds were listed and screened via the Swiss ADME tool and PAINS Remover; 303 compounds were filtered including active and similar drug compounds. The targets were retrieved from similar drugs of the active compounds of KSK. Finally, 573 genes were listed after several screening steps. Next, network analysis was performed to finalize the potential target gene: construction of protein-protein interaction of 573 genes using STRING, identifying top hub genes in Cytoscape plug-ins (MCODE and cytoHubba). These ten hub genes play a crucial role in the inflammatory response. Target-miRNA interaction was also constructed using the miRNet tool to interpret miRNAs of the target genes and their functions. Functional annotation was done via DAVID to gain a complete insight into the mechanism of the enriched pathways and other diseases related to the given target genes. In Molecular Docking analysis, IL10 attained top rank in Target-miRNA interaction and also the gene formed prominent exchanges with an excellent binding score (> = -8.0) against 19 compounds. Among them, Guggulsterone has an acute affinity score of -8.8 for IL10 and exhibits anti-inflammatory and immunomodulatory properties. Molecular Dynamics simulation study also performed for IL10 and the interacting ligand compounds using GROMACS. Finally, Guggulsterone will be recommended to enhance immunity against several inflammatory diseases, including COVID19.

Simultaneous Quantification of Piperine, Vasicine and Eugenol in <i>Kabasura Kudineer</i> by HPTLC

Kabasura Kudineer is a polyherbal decoction of the Siddha medical system (an Indian system of medicine), traditionally used to cure fever, colds, coughs, and respiratory ailments. The government of India had recommended Kabasura Kudineer as one of many preventive/treatment measures for COVID-19. Kabasura Kudineer Choornam is an admixed coarse powder of 15 herbs and its decoction is Kabasura Kudineer. The chemical constituents in the 15 herbs used for the preparation of the Choornam are known but the constituents present in the Kabasura Kudineer (decoction) are unidentified. Piperine, vasicine and eugenol are known for their potent activity against respiratory tract infections; hence, they were selected as marker compounds. The present work was planned to simultaneously quantify piperine, vasicine and eugenol in Kabasura Kudineer by the HPTLC method. The optimised mobile phase was toluene: ethyl acetate: methanol: ammonia (5:9:3:0.5, v/v/v/v), and the scanning was carried out at 287 nm. The Rf values of piperine, vasicine and eugenol were found to be 0.70, 0.32 and 0.82, respectively. The linearity range of piperine and vasicine was 500-3000 ng spot–1 and it was 10–60 ng spot–1 for eugenol. The quantities of piperine, vasicine and eugenol in Kabasura Kudineer (100 mL) were 0.03, 0.056 and 0.035 % w/v, respectively. This developed method can be used to simultaneously quantify piperine, vasicine and eugenol in any polyherbal formulation.

GC-MS AND OPTICAL CHARACTERIZATION, BIOLOGICAL PROPERTY STUDIES OF ETHANOLIC EXTRACT OF KABASURAKUDINEER AND MOLECULAR DOCKING INVESTIGATION OF (E)-3-PHENYL-1-(2, 2, 4- TRIMETHYLQUINOLIN-1-YL) PROP-2-EN-1-ONE

The recent global COVID-19 pandemic has drawn awareness among the people towards Kabasura Kudineer (KSK) and its healthcare benefits in Tamil Nadu, India. It has been traditionally used for effective management of respiratory ailments such as flu and colds. Nine Phytochemicals were identified through the Gas ChromatographyMass Spectrometry (GCMS) study, from the KSK extract with ethanol. Fourier transforms infrared (FT-IR), FTRAMAN, and UV studies were carried out for spectral investigations on the same KSK extract. The in vitro evaluation reveals the antimicrobial, cytotoxicity, and anticancer activity against human carcinoma (HT29) cells. One of the compounds was utilized for AutoDocking to check the anticancer efficacy of the KSK extract.

MiRNA-15/IL-10Rα axis promotes Kabasura Kudineer (Indian traditional Siddha formulation) induced immunomodulation by suppressing oxidative stress

Ethnopharmacological relevanceKabasura Kudineer (KK), the traditional Indian medicine of Siddha, effectively manages common respiratory symptoms such as flu, cold, and fever. However, there is no evidence of the immunomodulatory capacity of KK in the cultured Jurkat T-lymphocytes under the LPS insult studied. Aim of the studyAssess the effect of the traditional Indian medicine of Siddha, Kabasura Kudineer (KK) on immunomodulation by suppressing oxidative damage in cultured Jurkat T cells in vitro. The miRNA activity on anti-inflammatory gene receptors and cellular nitric oxide levels also was studied. Materials and methodsJurkat T cells were exposed to LPS treatment in the presence or absence of KK. Cell viability and nitric oxide (NO) were measured with MTT and Griess assay. Cellular antioxidant systems (glutathione and SOD) were determined using glutathione and SOD assay. Lipid peroxidation was measured using an MDA assay. MiRNA-15a-5p expression was performed using microRNA qPCR Assays. Both inflammatory and anti-inflammatory genes (IL-6, IL-1, IL-10, IL-13) were performed using a qPCR and ELISA assay. ResultsThe data showed that reduced cell proliferation and exaggerated NO production was observed in LPS treated condition compared to the control condition. Further, LPS treatment increased lipid peroxidation and reduced antioxidant enzyme activities (SOD and glutathione) in cultured Jurkat T cells. However, treatment with KK or N-acetyl cysteine (NAC; antioxidant) treatment mitigates the above effect. Mechanistically, LPS-induced oxidative stress upregulated miR- 15-5p expression and suppressed IL-10 Receptor alpha (IL-10Rα) by binding to its 3′-UTR region. The deregulated expression of IL-10Rα expression leads to increased IL-6 and IL-1β expression in LPS-induced Jurkat T cells; however, treatment with KK or NAC reversed the above effects. ConclusionCollectively, our study revealed the previously undefined mechanistic role of Kabasura Kudineer (KK) that alleviates the LPS-induced oxidative damage associated with inflammation by inhibiting the miRNA-15-5p/IL-10Rα axis.

Antidiabetic activity of Kabasura Kudineer Chooranam.

One of the traditional plants used in Siddha medicine is Kabasura Kudineer Chooranam. It is said to possess antiaging, life-strengthening, and disease-preventing activities that have an enormous influence on health care. It has significant therapeutic potential and ethnobotanical significance. The aim of this study is to investigate the antidiabetic activity of Kabasura Kudineer Chooranam. The antidiabetic potential of Kabasura Kudineer Chooranam was determined in vitro using established methods such as alpha-amylase and alpha-glucosidase activity. We used one-way ANOVA to see the statistical difference among the groups. The significance thresholds were considered at the P < 0.05 level. In comparison with the healthy group, the extract showed a significant antidiabetic effect. The proportion of inhibition increased as the concentrations increased. Previous studies established the antiviral, anti-inflammatory, analgesic, antifungal, antioxidant, antibacterial, hepatoprotective, antiasthmatic, immunomodulatory, and antipyretic effects of Kabasura Kudineer or Choornam. The current findings demonstrated that the Chooranam has good antidiabetic action at a significant concentration. Plant-based products have recently proven to be effective and economical antidiabetic items.

AYUSH (Indian System of Medicines) Therapeutics for COVID-19: A Living Systematic Review and Meta-Analysis (First Update).

Background: In India, alternative and complementary therapies (Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy [AYUSH] medicines) are extensively utilized in COVID-19 management, and some were investigated clinically. This study assessed the effectiveness of AYUSH therapeutic on COVID-19 through a living systematic review and meta-analysis approach. Methods: Databases like PubMed; the Cochrane central register of controlled trials; WHO COVID-19 database; the central trial registry-India; Digital Helpline for Ayurveda Research Articles and AYUSH research portal, and preprint repositories were searched till August 1, 2021. Randomized controlled trials or analytical observational studies were included only. Primary outcomes selected were clinical improvement, WHO ordinal scale, viral clearance, and mortality, whereas secondary outcomes were the use of O2 therapy or mechanical ventilator, admission to high dependency unit or emergency unit, duration of hospitalization, the time to symptom resolution, and adverse events. The risk of bias was evaluated by Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB-2) and Risk of Bias in Nonrandomized Studies-of Interventions (ROBINS-I) tools; data were synthesized through RevMan 5.4 tool, and the certainty of the evidence was ranked through the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Results: Of 3609 studies retrieved, 17 were included in the systematic review, and 3 AYUSH therapeutics were meta-analyzed. Meta-analysis suggested that add-on AYUSH-64 likely provides therapeutic benefits by reducing time to symptom resolution (mean difference [MD] 2.35 days lower [95% confidence interval, CI; 4.05 lower to 0.65 lower]) and hastening clinical improvement (365 more per 1000 [95% CI; 4 more to 1000 more]) in mild-to-moderate COVID-19 patients. Kabasura Kudineer adjuvant to standard care is likely to reduce symptom resolution (MD; 1.93 days lower [95% CI; 2.28 lower to 1.58 lower]) and hospital stay (MD; 4.2 days lower [95% CI; 4.97 lower to 3.43 lower]) in mild-to-moderate COVID-19 patients. Co-administration of Guduchi (Tinospora cordifolia [Willd.] Miers.) to standard care may reduce the duration of hospitalization (MD; 3.93 days, lower [95% CI; 8.83 lower to 0.97 higher]) in mild-to-moderate COVID-19 patients. Furthermore, all three agents seemed safe in adjunct usage to standard care. The certainty of evidence for most outcomes was moderate to low, primarily due to the high risk of bias or imprecision owing to the small sample size. Conclusion: Rational use of integrated or standalone AYUSH interventions in mild-to-moderate COVID-19 patients is safe and may provide therapeutic benefits. The effect estimates may be changed with additional evidence in upcoming updates.

Therapeutic Efficacy of Polyherbal Formulation Kabasura kudineer Against Common Viral Fevers - A Perspective Review

Background: COVID-19 viral infection is a worldwide pandemic that created a major concern regarding the need for a suitable drug candidate for viral infections. The entire scientific community is putting up their entire efforts and research to find a proper cure for this. The traditional Indian Siddha system of medicine is one of the oldest forms of medicine which includes medicine, Varma, alchemy, yoga, and rejuvenation. Methods: Kabasura kudineer is one of the Siddha herbal preparations that are being recommended by the State government of Tamilnadu, India for protection against COVID-19. It is recommended due to its claims to have anti-viral properties and other numerous health benefits. Results: This article provides a thorough examination of the Kabasurakudineer which is a polyherbal formulation comprising 15 powerful ancient Indian herbals in it that possess various potential phytochemicals providing numerous therapeutic activities. Also, the review highlights the most important therapeutic benefits of this formulation like anti-viral properties along with other activities such as immunomodulatory, bronchodilatory, anti-asthmatic, etc., Conclusion: The role of Kabasurakudineer against viral diseases especially the recent COVID-19 is tremendous and there is a need to enhance further research on this powerful formulation to make it more efficient and useful to the entire people community.

PROSPECTIVE INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF SIDDHA INTERVENTION KABASURA KUDINEER AS A PROPHYLACTIC MEASURE AMONG HIGH RISK POPULATION EXPOSED TO COVID-19

Background: Covid19 a massive threat to public health worldwide addressed the need of Clinical interventions to decrease the incidence and severity of illness. Aim of the study is to assessObjectives: the effectiveness of Siddha intervention- Kabasura Kudineer in prophylaxis of COVID-19 with the assessment of laboratory parameters before and after intervention. The secondary objective is observance of any Adverse Reaction due to consumption of Kabasura Kudineer. The subjects selected for the study are initially subjected to clinical examination, biochemicalMethods: Investigation, assessment of Immune status and quality of life. Kabasura Kudineer was given to the subjects and advised to take it as per the prescribed dosage for 14 days. Subjects was observed for occurrence of mild to moderate symptoms of COVID-19. The follow-up period is another 14 days and after that, the clinical assessment was carried out. The clinicalResults: assessment of 400 subjects enrolled showed improvement in quality of life through WHO-QOL-BREF assessment. The ISQ score is increased in all cases after the intake of Kabasura Kudineer and follow-up. There was no incidence of Covid 19 in subjects taken the Siddha intervention. Haemoglobin level of 76% Subjects taken KSK showed strong positive correlation (r = 0.9) and great signicance (t18 = -5.29, p &lt; 0.001) with 95% CI. The RBC count value of 56% subjects treated with KSK exhibited strong positive correlation (r = 0.87) and signicance (t13 = 4.41, p &lt; 0.001). No incidence of COVID-19 in highConclusion: risk population of this interventional study concludes that the immunomodulatory activity of the drug may support for the prevention of Covid 19 infection.

Safety and efficacy of a Siddha Medicine fixed regimen for the treatment of asymptomatic and mild COVID-19 patients

BackgroundThe Coronavirus disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a massive threat to public health worldwide. Siddha system of medicine is one of the traditional medicines of South India. The recommended formulations in Siddha Sasthric Medicines- Fixed Regimen (SSM-FiRe) are Amukkura tablets, Kaba Sura Kudineer (KSK) for asymptomatic COVID-19 positive (RT-PCR) patients, and Athimathuram tablets, Adathodai Manappagu syrup, Thippili Rasayanam, Brahmananda Bairavam tablet, and Notchi Kudineer for mild symptomatic patients. The core objective of the trial was to document the efficacy of SSM-FiRe in the prevention of asymptomatic and mild COVID-19 disease progression to the next level of severity, reduce the severity of symptoms and revert to RT-PCR Negative. MethodsAn exploratory, prospective, open-labeled, single-arm, non-randomized trial was designed as per GCP guidelines to assess the efficacy of SSM-FiRe. Sixty RT-PCR positive participants who were asymptomatic or with mild COVID-19 symptoms were recruited for the study at the Siddha COVID Care Centre, Vyasarpadi, Chennai from June to August 2020. Nasal and oropharyngeal swab tests were performed on the 0, 7th, and 14th days. All participants were treated with SSM – FiRe regimen. All the participants were also assessed based on Siddha Yakkkaiyin Ilakkanam, which included Clinical symptoms and vitals. Laboratory investigations such as Haemogram, Liver Function Test, Renal Function Test, HbA1C, Electrolytes, Inflammatory markers, Cardiac profile, Immunoglobulins, and anti-SARS-CoV-2 antibody tests were performed. Results83% of COVID-19 patients turned RT-PCR negative on the 7th day and in most of the cases, symptoms were reduced within the first 5 days of admission. The RT-PCR cycle threshold (ct) value increased significantly (<0.001) after treatment and all the participants were RT-PCR negative, except one, who was positive even after 14 days. Anti-SARS-CoV-2 antibodies developed significantly (p-value – 0.006). LFT, RFT, CBC, Total proteins, and electrolytes continued to be in the normal range after treatment, indicating the safety of the intervention. ConclusionAsymptomatic and mild COVID-19 disease can be well managed by SSM – FiRe treatment, Further studies could be taken up to strengthen the findings.

Acute Respiratory Distress Syndrome due to COVID-19 in India and efficacy of Indian Siddha drugs - A Trial of Lopinavir-Ritonavir

Novel coronavirus pneumonia (COVID-19) is a respiratory infection caused by infecting lungs and respiratory pathways which has rapidly spread to 216 countries. It is causing serious harm to the world’s entire population and a huge social burden, which can spread mainly by droplets produced during coughing and sneezing from animal to animal or human to human. There were no drugs or vaccines available as of May 2020. Though the severity and infectious behavior and mortality rate of COVID-19 led to the discovery of various vaccines and drugs that are available to control COVID-19 pandemic. India has two vaccines: Covishield and Covaxin approved by the Government of India on 2nd January 2021. Of this sudden and lethal disease, the traditional Indian siddha medicine was proficient as an alternative source, in performing differentiation with fewer side effects and better ability to prevent and control. In this article, we have comprehensively analyzed the case study and the efficacy of Indian Siddha medicine Kabasura Kudineer chooranam. Naturally occurring Indian Siddha medicinal (Kabasura Kudineer chooranam) compounds and its treatment as prevention measures so as to provide strategy and suggestions for the disease COVID-19 are discussed.

Precise and quick detection of ascorbic acid and eugenol in fruits, pharmaceuticals and medicinal herbs using hydroxyapatite-titanium dioxide nanocomposite-based electrode

Ascorbic acid (AA) and eugenol (EUG) are well-known antioxidants found in several fruits, spices and herbs. In particular, the EUG, one of the major phytocompounds present in clove, acts as pro-oxidant or anti-oxidant depending on its concentration. Considering the medical importance of AA and EUG and its extensive usage in the form of food and medicine, we have developed a voltammetric sensor based on hydroxyapatite-TiO2 composite modified GCE for their selective and simultaneous determination over very wide linear range of 2.78–2490 µM for AA and 1.4–78 µM for EUG with the LODs of 63.3 nM and 94 nM respectively. Practical applicability of the prepared electrode has been demonstrated by detecting AA and EUG in lemon juice, vitamin tablet, clove oil and Kabasura Kudineer, an herbal decoction used as an immunity booster against number of diseases including Covid-19. The proposed HAP-TiO2/GCE shall be useful for food and pharmaceutical industries.

Computational Study on the Inhibitory Effect of Natural Compounds against the SARS-CoV-2 Proteins.

COVID-19 is more virulent and challenging to human life. In India, the Ministry of AYUSH recommended some strategies through Siddha, homeopathy, and other methods to effectively manage COVID-19 (Guidelines for AYUSH Clinical Studies in COVID-19, 2020). Kabasura Kudineer and homeopathy medicines are in use for the prevention and treatment of COVID-19 infection; however, the mechanism of action is less explored. This study aims to understand the antagonist activity of natural compounds found in Kabasura Kudineer and homeopathy medicines against the SARS-CoV-2 using computational methods. Potential compounds were screened against NSP-12, NSP-13, NSP-14, NSP-15, main protease, and spike proteins. Structure-based virtual screening results shows that, out of 14,682 Kabasura Kudineer compounds, the 250395, 129677029, 44259583, 44259584, and 88583189 compounds and, out of 3,112 homeopathy compounds, the 3802778, 320361, 5315832, 14590080, and 74029795 compounds have good scoring function against the SARS-CoV-2 structural and nonstructural proteins. As a result of docking, homeopathy compounds have a docking score ranging from −5.636 to 13.631 kcal/mol, while Kabasura Kudineer compounds have a docking score varying from −8.290 to −13.759 kcal/mol. It has been found that the selected compounds bind well to the active site of SARS-CoV-2 proteins and form hydrogen bonds. The molecular dynamics simulation study shows that the selected compounds have maintained stable conformation in the simulation period and interact with the target. This study supports the antagonist activity of natural compounds from Kabasura Kudineer and homeopathy against SARS-CoV-2's structural and nonstructural proteins.

Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmissions are occurring rapidly; it is raising the alarm around the globe. Though vaccines are currently available, the evolution and mutations in the SARS-CoV-2 threaten available vaccines' significance. The drugs are still undergoing clinical trials, and certain medications are approved for “emergency use” or as an “off-label” drug during the pandemic. These drugs have been effective yet accommodating side effects, which also can be lethal. Complementary and alternative medicine is highly demanded since it embraces a holistic approach. Since ancient times, natural products have been used as drugs to treat various diseases in the medical field and are still widely practiced. Medicinal plants contain many active compounds that serve as the key to an effective drug design. The Kabasura kudineer and Nilavembu kudineer are the two most widely approved formulations to treat COVID-19. However, the mechanism of these formulations is not well known. The proposed study used a network pharmacology approach to understand the immune-boosting mechanism by the Kabasura kudineer, Nilavembu kudineer, and JACOM in treating COVID-19. The plants and phytochemical chemical compounds in the Kabasura kudineer, Nilavembu kudineer, and JACOM were obtained from the literature. The Swiss target prediction algorithm was used to predict the targets for these phytochemical compounds. The common genes for the COVID-19 infection and the drug targets were identified. The gene–gene interaction network was constructed to understand the interactions between these common genes and enrichment analyses to determine the biological process, molecular functions, cellular functions, pathways involved, etc. Finally, virtual screening and molecular docking studies were performed to identify the most potential targets and significant phytochemical compounds to treat the COVID-19. The present study identified potential targets as ACE, Cathepsin L, Cathepsin B, Cathepsin K, DPP4, EGFR, HDAC2, IL6, RIPK1, and VEGFA. Similarly, betulinic acid, 5″-(2⁗-Hydroxybenzyl) uvarinol, antofine, (S)-1′-methyloctyl caffeate, (Z)-3-phenyl-2-propenal, 7-oxo-10α-cucurbitadienol, and PLX-4720 collectively to be potential treatment agents for COVID-19.

Awareness On Role of Kabasura Kudineer on Immunity Among Adult Population

Awareness On Role of Kabasura Kudineer on Immunity Among Adult Population